Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5683-5690

  Zhou, Zongxiang ^a   Flesken Nikitin, Andrea ^a   Nikitin, Alexander Yu ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL MARKER; CHROMOGRANIN A; CYTOKERATIN 8; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL MUTANT; CLINICAL FEATURE; CONTROLLED STUDY; MALE; METASTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STEM CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34250822389     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0768     Document Type: Article

References (53)

1. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287-96.
2. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-48.
3. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. Washington: Armed Forces Institute of Pathology; 2000.
4. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001;12 Suppl 2:S141-4.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
6. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci U S A 1998;95:15382-7.
7. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 2005;108:1-11.
8. Sugimura Y, Cunha GR, Donjacour AA. Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 1986;34:961-71.
9. Lee C, Sensibar JA, Dudek SM, Hiipakka RA, Liao ST. Prostatic ductal system in rats: regional variation in morphologic and functional activities. Biol Reprod 1990;43:1079-86.
10. Tsujimura A, Koikawa Y, Salm S, et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 2002;157:1257-65.
11. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005;102:6942-7.
12. Burger PE, Xiong X, Coetzee S, et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci U S A 2005;102:7180-5.
13. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A 2007;104:181-6.
14. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 2006;103:1480-5.
15. Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 2006;66:7889-98.
16. Chai Y, Jiang X, Ito Y, et al. Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development 2000;127:1671-9.
17. Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. Fate of the mammalian cardiac neural crest. Development 2000;127:1607-16.
18. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003;63:3459-63.
19. Bonnerot C, Nicolas JF. Application of LacZ gene fusions to postimplantation development. Methods Enzymol 1993;225:451-69.
20. +/- mice. Cancer Res 2005;65:787-96.
21. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994-1004.
22. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29:418-25.
23. Wu X, Wu J, Huang J, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001;101:61-9.
24. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
25. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Mycdriven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
26. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
27. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate 2006;66:1013-28.
28. Mirosevich J, Gao N, Matusik RJ. Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate 2005;62:339-52.
29. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19:91-8.
30. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993;100:393-8.
31. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 1993;423:291-4.
32. Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the prostate. Development 2004;131:4955-64.
33. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
34. Robinson EJ, Neal DE, Collins AT. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998;37:149-60.
35. Hayward SW, Haughney PC, Lopes ES, Danielpour D, Cunha GR. The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate 1999;39:205-12.
36. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol 2002;12:401-6.
37. Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ. Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer 2004;91:1842-50.
38. Scaltriti M, Brausi M, Amorosi A, et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004;108:23-30.
39. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-21.
40. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902.
41. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
42. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003;425:962-7.
43. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005;19:1432-7.
44. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003;423:302-5.
45. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-8.
46. Cheng T, Scadden DT. Cell cycle regulators in stem cells. In: Lanza R, Blau H, Melton D, et al., editors. Handbook of stem cells. Burlington: Elsevier Academic Press; 2004. p. 73-82.
47. Wenzel PL, Wu L, de Bruin A, et al. Rb is critical in a mammalian tissue stem cell population. Genes Dev 2007;21:85-97.
48. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. ''Stemness'': transcriptional profiling of embryonic and adult stem cells. Science 2002;298:597-600.
49. Sherley JL, Stadler PB, Johnson DR. Expression of the wild-type p53 antioncogene induces guanine nucleotide-dependent stem cell division kinetics. Proc Natl Acad Sci U S A 1995;92:136-40.
50. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-73.
51. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol 2003;10:1924-33.
52. Eastham JA, Stapleton AM, Gousse AE, et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995;1:1111-8.
53. Li C, Larsson C, Futreal A, et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998;16:481-7.